Hot topics in adeno-associated virus as a gene transfer vector

Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology

Volumn 19, Issue 3, 2001, Pages 229-237

  Zhao, N ^a   Liu, D P ^a   Liang, C C ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Adeno associated virus; Application; Gene therapy; Integration; Package capacity; Transduction

Indexed keywords

HELICASE; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ARTICLE; DNA PACKAGING; GENE INSERTION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; IMMUNE RESPONSE; NONHUMAN; RECOMBINANT DNA TECHNOLOGY; VIRUS DNA CELL DNA INTERACTION;

DEPENDOVIRUS; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; TRANSFECTION;

EID: 0035168925     PISSN: 10736085     EISSN: None     Source Type: Journal    
DOI: 10.1385/MB:19:3:229     Document Type: Article

References (58)

1. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication
2. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus
3. Membrane-associated heparan sulfate proteoglycan I a receptor for adeno-associated virus type 2 virions
4. ¶¡V¶(logical not) 5 integrin: A co-receptor for adeno-associated virus type 2 infection
5. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
6. Dynamin is required for recombinant adeno-associated virus type 2 infection
7. Adeno-associated virus Rep78 protein and terminal repeats enhance integration of DNA sequences into the cellular genome
8. Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector
9. Left of what? The role of egocentric coordinates in neglect
10. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus type 2
11. Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
12. Cloning and characterization of adeno-associated virus type 5
13. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression
14. Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells
15. Site-specific integration of a transgene mediated by a hybrid adenovirus/adeno-associated virus vector using the Cre/loxP-expression-switching system
16. Viral vectors for gene delivery and gene therapy within the endocrine system
17. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus
18. Factors influencing recombinant adeno-associated virus production
19. High-titer, wild-type free recombinant adeno-associated virus vector production using intron-containing helper plasmids
20. Optimised helper virus-free production of high-quality adeno-associated virus vectors
21. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap
22. Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus
23. Analysis of recombinant adeno-associated virus packaging and requirements for rep and cap gene products
24. Gene transfer to the nigrostriatal system by hybrid herpes simplex virus/adeno-associated virus amplicon vectors
25. Efficient expression of CFTR function with adeno-associated vectors that carry shortened CFTR genes
26. Concatamerization of AAV circular genomes occurs through intermolecular recombination
27. Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver
28. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors
29. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy
30. Transduction of dendritic cells by DNA viral vectors directs the immune respone to trandgene products in muscle fibers
31. Efficient long term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
32. L3T4 T cells able to mediate parasite-specific delayed-type hypersensitivity play a role in the pathology of experimental Chagas' disease
33. Immune responses to adenovirus and adeno-associated virus in humans
34. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration
35. Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors
36. Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure
37. Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes
38. Adeno-associated virus 2-mediated gene transfer in murine hematopoietic progenitor cells
39. Long term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
40. Gene transfer into the mouse retina mediated by an adeno-associated viral vector
41. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver
42. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease
43. α V β 5 integrin: A co-receptor for adeno-associated virus type 2 infection
44. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hemotocrit in nonhuman primates
45. Transduction of well-differentiated airway epithelium by recombinant adeno-associated virus is limited by vector entry
46. Persistent, therapeutically relevant levels of human granulocyte colony-stimulating factor in mice after systemic delivery of adeno-associated virus vectors
47. Behavioral recovery in 6-hydroxydopamine lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic L-amino acid decarboxylase genes using two separate adeno-associated virus vectors
48. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors
49. Adeno-associated virus vector-mediated bcl-2 gene transfer into post-ischemic gerbil brain in vivo: Prospects for gene therapy of ischemia-induced neuronal death
50. Combined effects of adeno-associated virus vector and a herpes simplex virus mutant as neoplastic therapy
51. Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors
52. In utero delivery of adeno-associated viral vectors: Intraperitoneal gene transfer produces long-term expression
53. Selective cleavage of AAVS1 substrates by the adeno-associated virus type 2 rep68 protein is dependent on topological and sequence constraints
54. Site-specific integration of an adeno-associated virus vector plasmid mediated by regulated expression of rep based on Cre-loxP recombination
55. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long- term episome persistence in muscle tissue
56. Adeno-associated virus as a vector for liver-directed gene therapy
57. Recombinant adeno-associated virus for muscle directed gene therapy
58. Differential expression in human cells from the p6 promoter of human parvovirus B19 following plasmid transfection and recombinant adeno-associated virus 2 (AAV) infection: Human megakaryocytic leukaemia cells are non-permissive for AAV infection